• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Personal Genome Diagnostics adds James Lewis as SVP of Corporate Development

Personal Genome Diagnostics adds James Lewis as SVP of Corporate Development

January 19, 2017
CenterWatch Staff

Personal Genome Diagnostics (PGDx), a provider of advanced cancer genome testing products and services, has announced that James Lewis has joined the company as senior vice president of Corporate Development. Lewis brings broad biopharmaceutical industry experience to the development and execution of PGDx's growth strategy. He will oversee strategic planning, collaboration initiatives, and fundraising activities aimed at securing the requisite capital to meet short and long range corporate objectives, including launching a planned series B financing in 2017.

Doug Ward, chief executive officer of PGDx, said, "Jim brings us extensive life sciences industry leadership experience across a spectrum of business development and commercial roles, including managing strategic partnership transactions and equity financings, as well as developing and implementing commercialization initiatives for early and growth stage companies. We look forward to his many contributions during this time of rapid growth and expansion at PGDx."

Lewis commented, "PGDx has applied its deep expertise in cancer genomics to establish a thriving diagnostics business serving cancer researchers, drug developers, physicians and patients. This is an exciting time of scientific progress that offers significant new opportunities for genomics innovators such as PGDx. I am honored to support this outstanding team in their efforts to solve fundamental challenges in oncology."

Before joining PGDx, Lewis served as vice president, Business Development at Esperance Pharmaceuticals, a clinical stage oncology company, where he led strategic partnering and fundraising initiatives. During this time, he also served as a business consultant and advisor to a diverse group of emerging life science companies. Previously at AstraZeneca, he led business development activities for the cardiovascular franchise and was on the Crestor commercial team. Prior to AstraZeneca, Lewis held senior leadership positions in corporate strategy, business development and commercial operations at Biosyn, ViroPharma and TAP Pharmaceuticals. 

PGDx offers a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma-based options designed to address the specific research needs of cancer researchers and drug developers. PGDx's service offerings for researchers and testing labs are complemented by the clinical services it provides through its CLIA-certified laboratory. 

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing